NEW YORK (S&P Global Ratings) Oct. 6, 2021--S&P Global Ratings today said that it views Marlborough, Mass.-based Boston Scientific Corp.'s (BBB/Stable/A-2) recently announced acquisition of the cardiology business of Mississauga, Ontario-based Baylis Medical Co. Inc. for $1.75 billion as comfortably within the company's leverage capacity for the current rating. We expect the transaction to close in early 2022. We project Boston Scientific's leverage will be in the low-3x range in 2021 and 2022, well below our 3.75x downgrade threshold for the current rating, because it spends most of its internally generated cash flow on tuck-in acquisitions in high-growth therapeutic areas. We view the addition of Baylis' cardiovascular business, which we expect will generate close to $200 million in sales in
